Loveland, CO, United States of America

Gergo Hegedus

This inventor holds 1 USPTO granted patent. Top assignee: Agilent Technologies, Inc.. Active years: 2013.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Gergo Hegedus: Innovator in Oligonucleotide Sequencing

Introduction

Gergo Hegedus is a notable inventor based in Loveland, Colorado. He has made significant contributions to the field of biotechnology, particularly in the area of oligonucleotide sequencing. His innovative approach has the potential to enhance the accuracy and efficiency of genetic analysis.

Latest Patents

Gergo Hegedus holds a patent for a method of oligonucleotide sequencing by mass spectrometry. This computer-implemented method is designed to confirm the nucleotide sequence of an oligonucleotide. The process involves inputting the nucleotide sequence, executing an algorithm to predict molecular formulas of fragments, and comparing predicted m/z values to experimentally obtained values. This method is particularly useful for confirming the identity of synthesized oligonucleotides.

Career Highlights

Hegedus is currently employed at Agilent Technologies, Inc., where he continues to develop innovative solutions in the field of mass spectrometry and genetic sequencing. His work has contributed to advancements in biotechnology and has implications for various applications in research and diagnostics.

Collaborations

Gergo Hegedus collaborates with Zoltan Timar, a fellow innovator in the field. Their partnership exemplifies the collaborative spirit that drives innovation in scientific research.

Conclusion

Gergo Hegedus is a prominent figure in the realm of biotechnology, with a focus on oligonucleotide sequencing. His patented method represents a significant advancement in the field, showcasing his commitment to innovation and excellence.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…